Lipocine Inc (LPCN):企業の財務・戦略的SWOT分析

◆英語タイトル:Lipocine Inc (LPCN) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH190476FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥88,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥133,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Lipocine Inc (Lipocine) operates as a pharmaceutical company that develops and commercializes treatment for men’s and women’s health. The company’s pipeline products for men’s health include LPCN 1111 and LPCN 1021; and for women’s health include LPCN 1107. Its LPCN 1111 is an oral testosterone product candidate and LPCN 1021 is an oral testosterone replacement therapy with positive topline. Lipocine offers LPCN 1107, an oral hydroxyprogesterone caproate product for prevention of preterm birth. It develops patented technology based on lipidic compositions that form an optimal dispersed phase in the gastrointestinal environment for improved absorption of the insoluble drug. Its Lip’ral is a technology based on lipidic compositions that form optimal dispersed phase in the gastrointestinal environment. Lipocine is headquartered in Salt Lake City, Utah, the US.

Lipocine Inc Key Recent Developments

Mar 11,2021: Lipocine Announces Financial Results For The Year Ended December 31 2020
Mar 11,2021: Lipocine To Present At M Vest / Maxim Conference And At The Lytham Partners Conference
Mar 03,2021: Lipocine Announces Presentations on TLANDO™ at ENDO 2021 Conference
Jan 28,2021: Lipocine Closes Underwritten Public Offering Of Common Stock
Jan 26,2021: Lipocine Prices $25 Million Underwritten Public Offering Of Common Stock

This comprehensive SWOT profile of Lipocine Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Lipocine Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Lipocine Inc – Key Information
Lipocine Inc – Overview
Lipocine Inc – Key Employees
Lipocine Inc – Key Employee Biographies
Lipocine Inc – Key Operational Heads
Lipocine Inc – Major Products and Services
Lipocine Inc – History
Lipocine Inc – Company Statement
Lipocine Inc – Locations And Subsidiaries
Lipocine Inc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Lipocine Inc – Business Description
Lipocine Inc – Corporate Strategy
Lipocine Inc – SWOT Analysis
SWOT Analysis – Overview
Lipocine Inc – Strengths
Lipocine Inc – Weaknesses
Lipocine Inc – Opportunities
Lipocine Inc – Threats
Lipocine Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Lipocine Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Lipocine Inc, Key Information
Lipocine Inc, Key Ratios
Lipocine Inc, Share Data
Lipocine Inc, Major Products and Services
Lipocine Inc, History
Lipocine Inc, Key Employees
Lipocine Inc, Key Employee Biographies
Lipocine Inc, Key Operational Heads
Lipocine Inc, Other Locations
Lipocine Inc, Subsidiaries
Lipocine Inc, Key Competitors
Lipocine Inc, SWOT Analysis
Lipocine Inc, Ratios based on current share price
Lipocine Inc, Annual Ratios
Lipocine Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Lipocine Inc (LPCN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • ViaCyte Inc-製薬・医療分野:企業M&A・提携分析
    Summary ViaCyte Inc (ViaCyte), formerly Novocell, Inc. is a regenerative medicine company that focuses on the development of cell replacement therapies for the treatment of diabetes. The company’s pipeline product portfolio includes VC-01, which is being developed as a therapy for T1D patients who h …
  • A-Sonic Aerospace Limited:企業の戦略・SWOT・財務分析
    A-Sonic Aerospace Limited - Strategy, SWOT and Corporate Finance Report Summary A-Sonic Aerospace Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Kalvista Pharmaceuticals Inc (KALV):医療機器:M&Aディール及び事業提携情報
    Summary Kalvista Pharmaceuticals Inc (Kalvista), formerly Carbylan Therapeutics Inc, is a pharmaceutical company that discovers, develops and commercializes small molecule protease inhibitors. The company’s product candidates are inhibitors of plasma kallikrein, which is being developed for heredita …
  • Henry Schein Medical Systems Inc:医療機器:M&Aディール及び事業提携情報
    Summary Henry Schein Medical Systems Inc (HSMS), formerly MicroMD is a healthcare technology company that develops medical practice software solutions. The company provides practice management, EMR and document management software solutions for small practices, medical groups, community health cente …
  • Cyclenium Pharma Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Cyclenium Pharma Inc (Cyclenium Pharma) is a pharmaceutical research and development company that offers small molecule therapeutics agent producer for drug discovery. The company employs its proprietary customized macrocycles for recognition of topologies technology for discovering and deve …
  • Acxiom Corporation:企業の戦略・SWOT・財務分析
    Acxiom Corporation - Strategy, SWOT and Corporate Finance Report Summary Acxiom Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Corcept Therapeutics Inc (CORT):製薬・医療:M&Aディール及び事業提携情報
    Summary Corcept Therapeutics Inc (Corcept) is a research focused pharmaceutical company which discovers, develops and commercializes innovative therapeutics in the areas of psychiatric and metabolic diseases. The company focuses on developing drugs for the treatment of severe metabolic, oncologic an …
  • Apex Healthcare Berhad (AHEALTH):企業の財務・戦略的SWOT分析
    Apex Healthcare Berhad (AHEALTH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Ahimsa Industries Limited:戦略・SWOT・企業財務分析
    Ahimsa Industries Limited - Strategy, SWOT and Corporate Finance Report Summary Ahimsa Industries Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Bionik Laboratories Corp (BNKL):企業の財務・戦略的SWOT分析
    Summary Bionik Laboratories Corp (Bionik) is a medical device company that designs and develops transformational technologies, prosthetics and assisted robotic products and solutions. The company offers rehabilitation technology that senses patient movements and limitations. It provides lower body e …
  • Ygm Trading Ltd.:企業の戦略・SWOT・財務分析
    Ygm Trading Ltd. - Strategy, SWOT and Corporate Finance Report Summary Ygm Trading Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Yaskawa Electric Corp
    Yaskawa Electric Corp - Strategy, SWOT and Corporate Finance Report Summary Yaskawa Electric Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Berkshire Hills Bancorp, Inc.:企業のM&A・事業提携・投資動向
    Berkshire Hills Bancorp, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Berkshire Hills Bancorp, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Biafo Industries Ltd (BIFO):企業の財務・戦略的SWOT分析
    Biafo Industries Ltd (BIFO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • The Williams Companies Inc (WMB):企業の財務・戦略的SWOT分析
    The Williams Companies Inc (WMB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Clementia Pharmaceuticals Inc (CMTA)-製薬・医療分野:企業M&A・提携分析
    Summary Clementia Pharmaceuticals Inc (Clementia) is a biopharmaceutical company that develops and commercializes orphan drugs and therapies. The company’s palovarotene is used for treatment of muscle tissue disorders such as fibrodysplasia ossificans progressive and other diseases. Its palovarotene …
  • Tokuyama Corp (4043):電力:M&Aディール及び事業提携情報
    Summary Tokuyama Corp (Tokuyama), formerly Nihon Soda Kogyo Co., Ltd., manufactures and sells chemicals, specialty products and cement. Its product portfolio includes soda ash, caustic soda, silicon products, vinyl chloride monomer/polymer, fine chemicals, film products, medical materials, methylene …
  • Mustek Ltd (MST):企業の財務・戦略的SWOT分析
    Mustek Ltd (MST) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Transasia Bio-Medicals Ltd-医療機器分野:企業M&A・提携分析
    Summary Transasia Bio-Medicals Ltd (Transasia), a subsidiary of Erba Diagnostics Mannheim GmbH is an in-vitro diagnostic company that manufactures and exports diagnostic instruments and reagents. The company offers its products in various categories including clinical chemistry, immunology, diabetes …
  • Allied Technologies Limited:企業のM&A・事業提携・投資動向
    Allied Technologies Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Allied Technologies Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆